XML Cancer News

A numbers game: Math helps to predict how the body fights disease

published 1 day ago
(Walter and Eliza Hall Institute) Walter and Eliza Hall Institute researchers have defined for the first time how the size of the immune response is controlled, using mathematical models to predict how powerfully immune cells respond to infection and disease.

Survival differences seen for advanced-stage laryngeal cancer

published 1 day ago
(The JAMA Network Journals) The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy, or removal of the voice box, to treat the disease, despite a national trend toward organ preservation, according to a report published online by JAMA Otolaryngology-Head & Neck Surgery.

Study unlocks basis of key immune protein's two-faced role

published 2 days ago
(Brigham and Women's Hospital) A Brigham and Women's Hospital-led team has identified a long sought-after partner for a key immune protein, called TIM-3, that helps explain its two-faced role in the immune system.

Research team proves the efficacy of new drug against stem cells that provoke the growth of cancer

published 2 days ago
(University of Granada) An Andalusian team of researchers led by the University of Granada has designed a drug that fights cancerogenic stem cells responsible for the onset and development of cancer, for relapse after chemotherapy, and for metastasis. The new drug, called Bozepinib, has been successfully tested in mice, and has a selective action against cancerogenic stem cells for breast and colon cancer, as well as melanoma.

US supercomputer Titan does calculations for HZDR cancer research

published 2 days ago
(Helmholtz-Zentrum Dresden-Rossendorf) For their calculations, researchers at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) will now, starting in 2015, have access to the World's second-fastest computer. The Dresden research initiative is one of 56 projects the US Department of Energy has granted access to Titan as part of their INCITE program. HZDR's 3-D simulations of laser-accelerated ions is listed as one of their six 2015 highlights. Insights from the computations may prove useful in proton-based cancer therapy.